References

Multi-target approach to Alzheimer’s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid-modulating mechanisms

10.1007/s10048-025-00821-y · 2025 · External reference

The proline-rich hypothalamic peptide is a modulator of functions of neurotrophins and neuronal activity in amyloid-induced neurodegeneration

10.1134/s1819712414010036 · 2014 · External reference

Enhanced neuroprotection against Alzheimer’s disease by combining Inula viscosa with curcumin: an in vitro study

10.5114/aoms/201186 · 2025 · External reference

The duality of amyloid-β: its role in normal and Alzheimer’s disease states

10.1186/s13041-024-01118-1 · 2024 · External reference

The effect of apelin-13 on memory of scopolamine-treated rats and accumulation of amyloid-beta plaques in the hippocampus

10.61186/jcbr.7.4.15 · 2023 · External reference

Protein kinase C involvement in neuroprotective effects of thymol and carvacrol against toxicity induced by Amyloid-β in rat hippocampal neurons

10.32598/bcn.2021.666.2 · 2022 · External reference

Modulation of amyloid-β 1-42 structure and toxicity by proline-rich whey peptides

10.1039/c2fo30111c · 2012 · External reference

Treatment of Alzheimer’s disease: beyond symptomatic therapies

10.3390/ijms241813900 · 2023 · External reference

Targeted drug delivery: amyloid beta targeting drugs, immunotherapy, anti-tau and aggregation inhibitor, microtubule-stabilizing, and neuroinflammation modulation

2025 · External reference

Alzheimer's disease drug development pipeline: 2024

2024 · External reference

The cause of Alzheimer’s disease: the theory of multipathology convergence to chronic neuronal stress

10.14336/ad.2021.0529 · 2022 · External reference

Recent advances in molecular pathways and therapeutic implications targeting mitochondrial dysfunction for Alzheimer’s disease

10.1007/s12035-021-02612-6 · 2022 · External reference

Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25–35 model of Alzheimer's disease

10.1016/j.jalz.2007.10.019 · 2008 · External reference

Reimagining cholinergic therapy for Alzheimer’s disease

10.1093/brain/awac096 · 2022 · External reference

Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, challenges, and Limitations

10.1002/prp2.70131 · 2025 · External reference

Icariin as a new potential drug in Alzheimer disease treatment–a review

10.26444/jpccr/114763 · 2019 · External reference

The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer’s disease: therapeutic implications and future perspectives

10.3390/antiox11112167 · 2022 · External reference

Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: evidence for Aβ25–35

10.1016/j.expneurol.2009.09.005 · 2010 · External reference

Neuroprotective effect of Tozasertib in Streptozotocin-induced alzheimer’s mice model

10.1038/s41598-025-13920-5 · 2025 · External reference

Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer’s disease

10.1186/s12974-022-02613-9 · 2022 · External reference

Voglibose attenuates amyloid beta–induced memory deficits in a rodent model: a potential Alzheimer’s therapy via Wnt signaling modulation

10.1007/s12035-025-05047-5 · 2025 · External reference

Application of a histochemical method for detection of Ca2+ dependent acid phosphatase activity for studies of morpho-functional state of the cell structures in the rat brain

10.1134/s181971240804020x · 2008 · External reference

Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease

10.1152/physrev.00030.2022 · 2024 · External reference

Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state

10.1523/jneurosci.13-04-01676.1993 · 1993 · External reference

Alzheimer’s disease: from immune homeostasis to neuroinflammatory condition

10.3390/ijms232113008 · 2022 · External reference

Alzheimer's disease

10.1056/nejmra0909142 · 2010 · External reference

Amyloid beta in aging and Alzheimer’s disease

10.3390/ijms232112924 · 2022 · External reference

Emerging diagnostics and therapeutics for Alzheimer disease

10.1038/s41591-023-02505-2 · 2023 · External reference

The amyloid hypothesis of Alzheimer's disease at 25 years

10.15252/emmm.201606210 · 2016 · External reference

Aβ oligomers–a decade of discovery

10.1111/j.1471-4159.2006.04426.x · 2007 · External reference

Neuroprotective action of proline-rich polypeptide-1 in β-amyloid induced neurodegeneration in rats

10.1016/j.brainresbull.2011.08.003 · 2011 · External reference